Clinical Trial

A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Palmoplantar Pustulosis

Study acronym: BeSeen
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the efficacy and safety of bimekizumab compared with placebo in participants with palmoplantar pustulosis (PPP).
Protocol Amendment History 3 changes
notable Trial sites expanded: 77 -> 85 locations 2026-07-07
notable Trial sites expanded: 74 -> 77 locations 2026-06-23
notable Trial sites expanded: 41 -> 74 locations 2026-06-06
Trial Details
NCT Number NCT07219420
Lead Sponsor UCB Biopharma SRL
Conditions Palmoplantar Pustulosis
Enrollment 320 participants
Start Date 2025-11-14
Primary Completion 2027-12-27 (estimated)
Study Completion 2029-11-22 (estimated)
Updated on ClinicalTrials.gov 2026-07-17